Zandelisib Plus Rituximab Under Study in Indolent Non-Hodgkin Lymphoma
August 13th 2021Zandelisib plus rituximab is being evaluated as a potentially chemotherapy-free treatment strategy vs standard chemoimmunotherapy in patients with indolent non-Hodgkin lymphoma in first relapse in the ongoing, phase 3 COASTAL trial.
Topical BRAF Inhibitor, LUT014, Dosed in First US Patients With mCRC for Acneiform Lesions
August 10th 2021The first participants from the United States have been dosed with LUT014, a novel, topical BRAF inhibitor in a phase 2 trial that is evaluating the agent in patients with metastatic colorectal cancer who have developed dose-limiting acneiform lesions following treatment with an EGFR inhibitor.
GEN-1 Plus Neoadjuvant Chemo Appears Active, Safe in Advanced Ovarian Cancer
August 8th 2021The addition of GEN-1 to standard-of-care neoadjuvant chemotherapy has shown preliminary safety and clinical activity and appears to have an impact on the tumor microenvironment in patients with advanced epithelial ovarian cancer.